{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:34:41Z","timestamp":1740123281815,"version":"3.37.3"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10637-019-00865-6","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T01:22:02Z","timestamp":1571966522000},"page":"1196-1199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prolonged response to 177Lu-DOTATATE therapy of a bone marrow infiltration in a refractory thymic neuro endocrine tumor"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4805-4564","authenticated-orcid":false,"given":"Anne S\u00e9gol\u00e8ne","family":"Cottereau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9opoldine","family":"Bricaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Arrondeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amina","family":"Dechmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Montravers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Coriat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Clerc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Groussin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Tenenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"issue":"1","key":"865_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jtcvs.2014.08.061","volume":"149","author":"PL Filosso","year":"2015","unstructured":"Filosso PL, Yao X, Ahmad U, Zhan Y, Huang J, Ruffini E, Travis W, Lucchi M, Rimner A, Antonicelli A, Guerrera F, Detterbeck F, European Society of Thoracic Surgeons Thymic Group Steering C (2015) Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the international Thymic malignancy interest group and the European Society of Thoracic Surgeons databases. J Thorac Cardiovasc Surg 149(1):103\u2013109 e102. https:\/\/doi.org\/10.1016\/j.jtcvs.2014.08.061","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"865_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O\u2019Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Oberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E, Investigators N-T (2017) Phase 3 trial of (177)Lu-Dotatate for Midgut neuroendocrine tumors. N Engl J Med 376(2):125\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1607427","journal-title":"N Engl J Med"},{"issue":"16","key":"865_CR3","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen GJH, Krenning EP, Kwekkeboom DJ (2017) Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res 23(16):4617\u20134624. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2743","journal-title":"Clin Cancer Res"},{"issue":"3","key":"865_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","volume":"43","author":"H Bergsma","year":"2016","unstructured":"Bergsma H, Konijnenberg MW, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Franssen GJ, van Eijck CH, Krenning EP, Kwekkeboom DJ (2016) Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course. Eur J Nucl Med Mol Imaging 43(3):453\u2013463. https:\/\/doi.org\/10.1007\/s00259-015-3193-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"865_CR5","first-page":"437","volume":"3","author":"A Sabet","year":"2013","unstructured":"Sabet A, Khalaf F, Haslerud T, Al-Zreiqat A, Sabet A, Simon B, Poppel TD, Biersack HJ, Ezziddin S (2013) Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis. Am J Nucl Med Mol Imaging 3(5):437\u2013445","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"2","key":"865_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3413\/Nukmed-0614-13-08","volume":"53","author":"A Sabet","year":"2014","unstructured":"Sabet A, Khalaf F, Yong-Hing CJ, Sabet A, Haslerud T, Ahmadzadehfar H, Guhlke S, Grunwald F, Biersack HJ, Ezziddin S (2014) Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement. Nuklearmedizin 53(2):54\u201359. https:\/\/doi.org\/10.3413\/Nukmed-0614-13-08","journal-title":"Nuklearmedizin"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00865-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00865-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00865-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:40:46Z","timestamp":1678509646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00865-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["865"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00865-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2019,10,24]]},"assertion":[{"value":"3 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}